Gamma-Hydroxybutyrate Release Profile for Divalproex Co-Administration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for narcolepsy, such as sodium oxybate, fail to address the pharmacokinetic and pharmacodynamic interactions when Xyrem is co-administered with divalproex sodium without reducing the dosage of gamma-hydroxybutyrate and without compromising safety or efficacy.
Innovation Solution
A method of treating narcolepsy by administering a GHB composition concomitantly with divalproex sodium without reducing the dose of GHB, and vice versa, using a novel oral pharmaceutical composition that includes both immediate and modified release formulations of gamma-hydroxybutyrate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Xyrem is co-administered with divalproex sodium, then the treatment of narcolepsy is enhanced, but the systemic exposure to Xyrem increases by 25% causing greater impairment of attention and working memory
Solution Approach 1:
The patent divides the GHB composition into two distinct release portions: an immediate release portion and a modified release portion. This segmentation allows the drug to be delivered in a controlled manner, reducing the peak systemic exposure that causes cognitive impairment while maintaining therapeutic efficacy throughout the night.
Solution Approach 2:
The modified release portion provides periodic or sustained release of GHB over time, creating a more controlled pharmacokinetic profile. This periodic action prevents the sudden spike in systemic exposure that occurs with immediate release formulations, thereby reducing cognitive impairment while maintaining treatment effectiveness.
2Object-affected harmful factors
If the dosage of Xyrem is reduced to mitigate interactions with divalproex sodium, then cognitive impairment is reduced, but the treatment efficacy for narcolepsy symptoms is compromised
Solution Approach 1:
The patent employs a dynamic release system that adjusts the rate of GHB delivery over time. The immediate release portion provides initial therapeutic effect, while the modified release portion sustains the effect throughout the night. This dynamic approach maintains effective drug levels without requiring dose reduction, thereby preserving treatment efficacy while mitigating cognitive impairment.
Solution Approach 2:
The patent changes the pharmacokinetic parameters of GHB delivery by using different release mechanisms. The modified release portion extends the duration of action and flattens the concentration-time profile, allowing the same total dose to be administered without causing peak-related cognitive impairment, thus maintaining treatment efficacy.
3Speed
If immediate release formulation is used, then rapid sleep onset is achieved, but the duration of action is insufficient for sustained nighttime coverage
Solution Approach 1:
The patent segments the GHB composition into immediate release and modified release portions. The immediate release portion rapidly dissolves to produce quick sleep onset, while the modified release portion provides sustained drug delivery throughout the night. This segmentation allows both rapid onset and prolonged duration of action to be achieved simultaneously.
Solution Approach 2:
The patent merges two different release mechanisms into a single composition. The immediate release portion provides rapid onset, and the modified release portion extends duration. By combining these two mechanisms in one formulation, the patent achieves both fast sleep onset and sustained nighttime coverage without requiring separate medications.
Data Source
AI summary
Oral pharmaceutical compositions of gamma-hydroxybutyrate (GHB) suitable for concomitant administration with a dose of divalproex sodium (DVP) without materially altering the dosage amount of either drug are provided. Also provided are therapeutic uses of the compositions for the treatment of one or more symptoms of narcolepsy.